STOCK TITAN

[8-K] Bankunited, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. (DMAC) filed a Form 4 indicating that 10% owner Richard Jacinto II bought 400,000 voting common shares on 07/23/2025 at $3.50 per share. The filing was submitted on 07/25/2025.

The transaction, coded “P,” was executed indirectly through his NFS/FMTC Roth IRA. Following the purchase, the account holds 4,958,823 DMAC shares. Table II shows no derivative securities activity.

The report was filed by a single reporting person who remains subject to Section 16 obligations and lists indirect ownership of the acquired shares.

DiaMedica Therapeutics Inc. (DMAC) ha depositato un Modulo 4 che indica che Richard Jacinto II, proprietario del 10%, ha acquistato 400.000 azioni ordinarie con diritto di voto il 23/07/2025 al prezzo di 3,50 dollari per azione. La comunicazione è stata presentata il 25/07/2025.

L'operazione, codificata come “P,” è stata effettuata indirettamente tramite il suo NFS/FMTC Roth IRA. Dopo l'acquisto, il conto detiene 4.958.823 azioni DMAC. La Tabella II non mostra alcuna attività relativa a titoli derivati.

Il rapporto è stato presentato da una sola persona soggetta agli obblighi della Sezione 16 e indica la proprietà indiretta delle azioni acquisite.

DiaMedica Therapeutics Inc. (DMAC) presentó un Formulario 4 indicando que Richard Jacinto II, propietario del 10%, compró 400,000 acciones comunes con derecho a voto el 23/07/2025 a $3.50 por acción. La presentación se realizó el 25/07/2025.

La transacción, codificada como “P,” se ejecutó de manera indirecta a través de su NFS/FMTC Roth IRA. Tras la compra, la cuenta posee 4,958,823 acciones de DMAC. La Tabla II no muestra actividad en valores derivados.

El informe fue presentado por una sola persona reportante que sigue sujeta a las obligaciones de la Sección 16 y lista la propiedad indirecta de las acciones adquiridas.

DiaMedica Therapeutics Inc.(DMAC)는 10% 지분을 보유한 Richard Jacinto II가 2025년 7월 23일 주당 $3.50에 400,000표의 보통주를 매수했다는 내용을 담은 Form 4를 제출했습니다. 해당 신고는 2025년 7월 25일에 제출되었습니다.

“P” 코드로 표시된 거래는 그의 NFS/FMTC Roth IRA를 통해 간접적으로 실행되었습니다. 매수 후 해당 계좌는 4,958,823주의 DMAC 주식을 보유하고 있습니다. 표 II에는 파생증권 활동이 없습니다.

이 보고서는 단일 보고자가 제출했으며, 해당 보고자는 섹션 16 의무 대상자로서 취득한 주식의 간접 소유를 명시하고 있습니다.

DiaMedica Therapeutics Inc. (DMAC) a déposé un formulaire 4 indiquant que Richard Jacinto II, propriétaire de 10 %, a acheté 400 000 actions ordinaires avec droit de vote le 23/07/2025 au prix de 3,50 $ par action. Le dépôt a été effectué le 25/07/2025.

La transaction, codée « P », a été réalisée indirectement via son NFS/FMTC Roth IRA. Après cet achat, le compte détient 4 958 823 actions DMAC. Le tableau II ne montre aucune activité sur les titres dérivés.

Le rapport a été déposé par une seule personne déclarant, qui reste soumise aux obligations de la section 16 et indique la propriété indirecte des actions acquises.

Die DiaMedica Therapeutics Inc. (DMAC) reichte ein Formular 4 ein, das angibt, dass der 10%-Eigentümer Richard Jacinto II am 23.07.2025 400.000 stimmberechtigte Stammaktien zu je 3,50 USD gekauft hat. Die Meldung wurde am 25.07.2025 eingereicht.

Die Transaktion, codiert mit „P“, wurde indirekt über sein NFS/FMTC Roth IRA ausgeführt. Nach dem Kauf hält das Konto 4.958.823 DMAC-Aktien. Tabelle II zeigt keine Aktivitäten mit derivativen Wertpapieren.

Der Bericht wurde von einer einzelnen meldenden Person eingereicht, die weiterhin den Verpflichtungen gemäß Abschnitt 16 unterliegt und das indirekte Eigentum an den erworbenen Aktien angibt.

Positive
  • 400,000 shares purchased on 07/23/2025 at $3.50, totaling approximately $1.4 M.
  • Indirect holdings increased to 4,958,823 shares in the Roth IRA.
Negative
  • None.

Insights

TL;DR: 10% owner’s $1.4 M buy adds 400 K DMAC shares, lifting indirect stake to nearly 5 M—generally viewed as constructive insider activity.

The Form 4 discloses a sizeable open-market purchase (code “P”) at $3.50 per share, totaling roughly $1.4 million. Such accumulation by a 10% owner increases his indirect holdings to 4,958,823 shares, reinforcing alignment with shareholders. No sales or derivative transactions were reported, simplifying the ownership picture. While Form 4s do not provide strategic rationale, the scale of buying, relative to existing stake, is material and tends to be interpreted positively by the market.

DiaMedica Therapeutics Inc. (DMAC) ha depositato un Modulo 4 che indica che Richard Jacinto II, proprietario del 10%, ha acquistato 400.000 azioni ordinarie con diritto di voto il 23/07/2025 al prezzo di 3,50 dollari per azione. La comunicazione è stata presentata il 25/07/2025.

L'operazione, codificata come “P,” è stata effettuata indirettamente tramite il suo NFS/FMTC Roth IRA. Dopo l'acquisto, il conto detiene 4.958.823 azioni DMAC. La Tabella II non mostra alcuna attività relativa a titoli derivati.

Il rapporto è stato presentato da una sola persona soggetta agli obblighi della Sezione 16 e indica la proprietà indiretta delle azioni acquisite.

DiaMedica Therapeutics Inc. (DMAC) presentó un Formulario 4 indicando que Richard Jacinto II, propietario del 10%, compró 400,000 acciones comunes con derecho a voto el 23/07/2025 a $3.50 por acción. La presentación se realizó el 25/07/2025.

La transacción, codificada como “P,” se ejecutó de manera indirecta a través de su NFS/FMTC Roth IRA. Tras la compra, la cuenta posee 4,958,823 acciones de DMAC. La Tabla II no muestra actividad en valores derivados.

El informe fue presentado por una sola persona reportante que sigue sujeta a las obligaciones de la Sección 16 y lista la propiedad indirecta de las acciones adquiridas.

DiaMedica Therapeutics Inc.(DMAC)는 10% 지분을 보유한 Richard Jacinto II가 2025년 7월 23일 주당 $3.50에 400,000표의 보통주를 매수했다는 내용을 담은 Form 4를 제출했습니다. 해당 신고는 2025년 7월 25일에 제출되었습니다.

“P” 코드로 표시된 거래는 그의 NFS/FMTC Roth IRA를 통해 간접적으로 실행되었습니다. 매수 후 해당 계좌는 4,958,823주의 DMAC 주식을 보유하고 있습니다. 표 II에는 파생증권 활동이 없습니다.

이 보고서는 단일 보고자가 제출했으며, 해당 보고자는 섹션 16 의무 대상자로서 취득한 주식의 간접 소유를 명시하고 있습니다.

DiaMedica Therapeutics Inc. (DMAC) a déposé un formulaire 4 indiquant que Richard Jacinto II, propriétaire de 10 %, a acheté 400 000 actions ordinaires avec droit de vote le 23/07/2025 au prix de 3,50 $ par action. Le dépôt a été effectué le 25/07/2025.

La transaction, codée « P », a été réalisée indirectement via son NFS/FMTC Roth IRA. Après cet achat, le compte détient 4 958 823 actions DMAC. Le tableau II ne montre aucune activité sur les titres dérivés.

Le rapport a été déposé par une seule personne déclarant, qui reste soumise aux obligations de la section 16 et indique la propriété indirecte des actions acquises.

Die DiaMedica Therapeutics Inc. (DMAC) reichte ein Formular 4 ein, das angibt, dass der 10%-Eigentümer Richard Jacinto II am 23.07.2025 400.000 stimmberechtigte Stammaktien zu je 3,50 USD gekauft hat. Die Meldung wurde am 25.07.2025 eingereicht.

Die Transaktion, codiert mit „P“, wurde indirekt über sein NFS/FMTC Roth IRA ausgeführt. Nach dem Kauf hält das Konto 4.958.823 DMAC-Aktien. Tabelle II zeigt keine Aktivitäten mit derivativen Wertpapieren.

Der Bericht wurde von einer einzelnen meldenden Person eingereicht, die weiterhin den Verpflichtungen gemäß Abschnitt 16 unterliegt und das indirekte Eigentum an den erworbenen Aktien angibt.

0001504008false00015040082025-07-232025-07-230001504008exch:XNYS2025-07-232025-07-23


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 25, 2025 (July 23, 2025)

BankUnited, Inc.
(Exact name of registrant as specified in its charter)
Delaware 001-35039 27-0162450
(State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
14817 Oak Lane,Miami Lakes,FL                                                33016
(Address of principal executive offices)(Zip Code)
 
(Registrant’s telephone number, including area code): (305) 569-2000
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
                  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
                  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
                  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
                  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
ClassTrading SymbolName of Exchange on Which Registered
Common Stock, $0.01 Par ValueBKUNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act






Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

On July 23, 2025, BankUnited, Inc. (the “Company”) announced the hiring of James G. Mackey as a Senior Executive Vice President of Finance, effective as of August 15, 2025. Mr. Mackey is expected to succeed Leslie N. Lunak as Chief Financial Officer of the Company, effective as of November 1, 2025.

Mr. Mackey, 57, served as Senior Vice President and Chief Financial Officer of VIP Play, Inc., an innovative start-up company in the mobile sports gaming sector, from 2024 through August 2025. From 2020 through 2024, Mr. Mackey served as Executive Vice President and Chief Financial Officer of Wells Fargo’s consumer lending division, where he led the finance team supporting the newly formed division. His responsibilities included supporting strategic initiatives to optimize earnings, minimize operational risk, and increase enterprise value. From 2019 through 2020, Mr. Mackey served as Senior Advisor for the Federal Home Loan Mortgage Corporation (“FHLMC”), following his tenure as Chief Financial Officer of FHLMC from 2013 through 2019. As CFO, Mr. Mackey helped guide the strategic execution of an enterprise-wide transformation, implemented an updated capital management framework, and had a leadership role in initiatives to improve the overall housing finance system. From 2010 through 2013, Mr. Mackey served as Chief Financial Officer and Executive Vice President of Ally Financial where he previously held the position of Senior Finance Executive and Vice President from 2009 to 2010. From 1998 to 2009, Mr. Mackey served in various roles at Bank of America. Mr. Mackey began his career at PwC and holds a master’s degree in accounting and a bachelor’s degree in business administration from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill.

In connection with Mr. Mackey’s hiring, the Company and Mr. Mackey entered into an offer letter pursuant to which Mr. Mackey’s annual base salary will be $600,000, his target annual bonus opportunity will be $600,000 (prorated for 2025 based on his hire date) and his target annual equity award opportunity will be $800,000 (prorated for 2025 based on his hire date). In addition, in connection with his hire, Mr. Mackey will receive a restricted stock unit award with a grant date value of $1,000,000, 1/3 of which will vest on each of the first three anniversaries of the grant date, and a one-time relocation bonus of $150,000. If Mr. Mackey’s employment is involuntarily terminated without cause not in connection with a change in control, he will be eligible for severance benefits of six months base salary and six months of COBRA premiums, subject to his execution of a release of claims.

The Company and Mr. Mackey also entered into a retention letter providing for the opportunity to receive a retention bonus in the event of a change in control of the Company. If Mr. Mackey remains employed with the Company or its successor six months following a change in control, he will be eligible for a retention bonus equal to (a) three times his annual base salary, if the change in control occurs prior to the first anniversary of his continuous employment with the Company, (b) two times his annual base salary if the change in control occurs on or after the first anniversary of his continuous employment with the Company and prior to the second anniversary of his continuous employment with the Company or (c) one times his annual base salary if the change in control occurs on or after the second anniversary of his continuous employment with the Company. Mr. Mackey will also be eligible for the retention bonus if his employment is terminated without cause or due to a reduction in his base salary between the change in control and the date the retention bonus vests, subject to his execution of a release of claims.

The foregoing descriptions of the terms and conditions of the offer letter and retention letter with Mr. Mackey do not purport to be complete and are qualified in their entirety by reference to the full text thereof, which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.

1




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:July 25, 2025BANKUNITED, INC.
 /s/ Leslie N. Lunak
 Name:Leslie N. Lunak
 Title:Chief Financial Officer
2


EXHIBIT INDEX
Exhibit
Number
 Description
10.1
    BankUnited, Inc. Offer Letter for James G. Mackey
10.2
    BankUnited, Inc. Retention Letter for James G. Mackey
3

FAQ

How many DMAC shares did Richard Jacinto II buy on 07/23/2025?

He purchased 400,000 voting common shares.

What was the purchase price per share in the latest DMAC Form 4?

The shares were bought at $3.50 each.

What is Richard Jacinto II's total ownership after the transaction?

His indirect Roth IRA account now holds 4,958,823 DMAC shares.

Through which account were the DMAC shares acquired?

The acquisition was made via NFS/FMTC Roth IRA FBO Richard Jacinto II.

Were any derivative securities reported in this DMAC Form 4 filing?

No, Table II lists no derivative securities.
Bankunited Inc

NYSE:BKU

BKU Rankings

BKU Latest News

BKU Latest SEC Filings

BKU Stock Data

2.97B
74.52M
1.01%
102.37%
3.31%
Banks - Regional
Savings Institution, Federally Chartered
Link
United States
MIAMI LAKES